Peptide Advocate
Back to News

/ Peptide Advocate

Important Read!

Tirzepatide: what it is and how it works in your body

Tirzepatide is one of the most thoroughly studied metabolic medicines available. By copying two gut hormones at once, it reduces appetite, improves blood sugar control, and produces large, well-documented weight loss, with growing evidence for benefits to the heart, kidneys, liver, and sleep. It also has real side effects, works best as a long-term treatment, and is safest in its FDA-approved form under a qualified prescriber's care.

Tirzepatide: what it is and how it works in your body

One weekly injection, two hormone signals, and effects that reach from your brain to your liver. Here is what the research actually shows, in plain language.

Peptide Advocate · Evidence review · Updated September 2026

What it isA lab-made peptide that copies two natural gut hormones, GIP and GLP-1
Brand namesMounjaro (type 2 diabetes) and Zepbound (weight management, sleep apnea)
How it's takenA small injection under the skin, once a week
Headline resultAbout 21% average weight loss at the top dose in a 72-week trial6

What is tirzepatide?

Tirzepatide is a prescription medicine made by Eli Lilly. It is a peptide, meaning a short chain of amino acids (39 of them, in this case), designed to act like two hormones your gut already releases every time you eat.4 A fatty-acid "tail" attached to the chain lets it ride on proteins in your blood, so one injection keeps working for about a week.

In the U.S., tirzepatide is FDA-approved under two brand names. Mounjaro is approved to improve blood sugar control in adults with type 2 diabetes. Zepbound is approved, alongside a reduced-calorie diet and more physical activity, for long-term weight management in adults with obesity, or with overweight plus at least one weight-related health condition. Since December 2024, Zepbound is also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.1,14

How it works: one molecule, two signals

When you eat, your intestines release hormones called incretins. The two main ones are GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). They tell your pancreas to release insulin, and they help your brain register that you've eaten. Your body breaks natural GIP and GLP-1 down within minutes. Tirzepatide is built to resist that breakdown.

What makes tirzepatide different from older drugs such as semaglutide (Ozempic, Wegovy) is that it activates both receptors, not just the GLP-1 receptor. It is also deliberately lopsided: lab studies show it binds the GIP receptor about as strongly as natural GIP, while its pull on the GLP-1 receptor is roughly five times weaker than natural GLP-1.4 Researchers call this an "imbalanced" dual agonist, and they think the combination is part of why it lowers blood sugar and weight more than GLP-1 drugs alone.3

One molecule, two receptors Tirzepatide binds strongly to the GIP receptor and more weakly to the GLP-1 receptor on the surface of cells. Tirzepatideone peptide chain + a fatty-acid "tail" that makes it last a weekOutside the cellInside the cellGIP receptorGLP-1 receptorstrong fitweaker fitHelps the pancreas release insulinwhen blood sugar is highImproves how fat tissue storesand handles incoming energyBoosts insulin, lowers glucagonSlows how fast the stomach emptiesSignals fullness to the brain,which reduces appetite
Tirzepatide acts on two different receptors on the surface of cells. Diagram: Peptide Advocate.

A tour of the body

GIP and GLP-1 receptors sit in many tissues, so tirzepatide's effects show up in many places. Some effects are direct. Others, like easier breathing during sleep, come mostly from the weight loss itself.

Where tirzepatide acts in the body A body outline with callouts for the brain, airway, heart, liver, stomach, pancreas, kidneys and fat tissue, each with a short note on tirzepatide's effect. BrainTurns down hunger signalsand food "noise"; you feelfull soonerAirway & sleepWeight loss eases airwaycollapse; FDA-approved forsleep apnea with obesityLiverLess liver fat; early trialshowed fatty-liverinflammation resolvingKidneysSlower decline in kidneyfunction in a large hearttrial of people with diabetesHeart & vesselsLower blood pressure andfewer heart-failure eventsin people with obesityStomachEmpties more slowly, someals feel bigger andlast longerPancreasMore insulin when sugaris high, less glucagon;lowers A1CFat tissueLoses mostly fat, lesslean mass; GIP helps fathandle energy better
Where tirzepatide acts, and what studies have found in each area. Diagram: Peptide Advocate.

Brain: appetite and fullness

This is where most of the weight loss starts. GLP-1 and GIP receptors are found in brain regions that control hunger and food-seeking. Their patterns don't fully overlap, which scientists believe helps explain why hitting both receptors reduces weight more than hitting one.9 Many people describe feeling satisfied with smaller portions and thinking about food less often.

Stomach and gut: slower emptying

Tirzepatide slows how quickly food leaves the stomach, so a meal feels bigger and fullness lasts longer.1 This same effect causes the most common side effects (nausea, fullness, constipation, or diarrhea). It can also change how some pills you swallow are absorbed, which is why the label advises women on birth-control pills to use a backup or non-oral method for four weeks after starting and after each dose increase.2

Pancreas: smarter insulin release

Both hormones tell the pancreas's beta cells to release insulin, but only when blood sugar is elevated. That "glucose-dependent" design is why tirzepatide by itself rarely causes low blood sugar (the risk goes up when it's combined with insulin or sulfonylureas). GLP-1 signaling also lowers glucagon, a hormone that raises blood sugar. In a 26-week study of people with type 2 diabetes, tirzepatide improved markers of beta-cell function and insulin sensitivity more than the GLP-1 drug dulaglutide, and only part of the insulin-sensitivity gain was explained by weight loss.5

Fat tissue: losing mostly fat

GIP receptors on fat cells are thought to help fat tissue store and handle incoming energy more healthily. In SURMOUNT-1, body scans in a subgroup showed people lost about three times more fat (a 33.9% drop in fat mass) than lean mass (a 10.9% drop).7 Some lean-mass loss is normal with any large weight loss, which is why protein intake and strength training matter while on treatment.

Liver: less fat and inflammation

In SYNERGY-NASH, a phase 2 trial of 190 adults with fatty-liver inflammation (MASH) and moderate or severe scarring, the liver inflammation resolved without scarring getting worse in 44% to 62% of people on tirzepatide, compared with 10% on placebo, after 52 weeks.15 The trial was small and short, and tirzepatide is not FDA-approved for liver disease. Larger studies are underway.

Heart and blood vessels

The largest study so far, SURPASS-CVOT, followed more than 13,000 people with type 2 diabetes and heart disease for about four years. Heart attack, stroke, or cardiovascular death occurred in 12.2% of people on tirzepatide versus 13.1% on dulaglutide, a GLP-1 drug already proven to protect the heart. That met the bar for "at least as good" but not for "better."12 Deaths from any cause were 16% lower with tirzepatide.13

In SUMMIT, a trial of 731 people with obesity and a common type of heart failure (heart failure with preserved ejection fraction, or HFpEF), tirzepatide lowered the risk of cardiovascular death or worsening heart failure compared with placebo.16 Follow-up analyses found lower blood pressure (about 5 points systolic), less excess blood volume, 37% lower levels of the inflammation marker CRP,17 and less fat around the heart.16

Kidneys

In people at high risk of kidney disease in SURPASS-CVOT, kidney function declined more slowly on tirzepatide than on dulaglutide over three years.13 One caution: vomiting or diarrhea can cause dehydration, and the label warns this can lead to acute kidney injury. Drinking enough fluids matters, especially early on.2

Airway and sleep

Obstructive sleep apnea happens when the airway repeatedly collapses during sleep. In the SURMOUNT-OSA trials (469 adults with obesity), tirzepatide reduced breathing interruptions and led to the first FDA approval of any drug for sleep apnea, in December 2024.14 The benefit comes mainly from weight loss, so it applies to apnea linked to obesity, not to apnea caused by jaw or airway structure. Don't stop a CPAP machine without a repeat sleep study and your doctor's okay.

Still early: brain health. Reviews describe possible effects on inflammation and nerve cells that could matter for conditions like Alzheimer's and Parkinson's disease, but this evidence comes mostly from lab and animal studies.18 Treat claims about brain-health benefits as unproven for now.

What the major trials found

Tirzepatide has been tested in two large trial programs: SURPASS (type 2 diabetes) and SURMOUNT (weight management), plus trials for sleep apnea, heart failure, and liver disease.

Average weight loss after 72 weeks, SURMOUNT-1 Placebo 3.1 percent, tirzepatide 5 mg 15.0 percent, 10 mg 19.5 percent, 15 mg 20.9 percent average body-weight loss. Average weight lost after 72 weeksSURMOUNT-1: 2,539 adults with obesity or overweight, no diabetes0%−5%−10%−15%−20%−25%−3.1%Placebo−15.0%5 mg−19.5%10 mg−20.9%15 mgWeekly tirzepatide dose shown above each bar. Source: Jastreboff et al., NEJM 2022.
In SURMOUNT-1, all three doses produced far more weight loss than placebo.6 These are averages; individual results vary widely.
TrialWho was studiedKey finding
SURMOUNT-12,539 adults with obesity or overweight, no diabetes; 72 weeksAverage weight loss of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) vs. 3.1% on placebo6
SURMOUNT-1, 3 years1,032 of those adults who also had prediabetesFar fewer developed type 2 diabetes on tirzepatide than on placebo8
SURMOUNT-5751 adults with obesity; head-to-head vs. semaglutide20.2% average weight loss on tirzepatide vs. 13.7% on semaglutide at 72 weeks9
SURMOUNT-4670 adults after 36 weeks of treatmentStopping led to substantial weight regain (see below)10
SURMOUNT-OSA469 adults with obesity and moderate-to-severe sleep apneaFewer breathing interruptions; led to FDA approval for sleep apnea14
SURPASS-CVOT13,165 adults with type 2 diabetes and heart disease; ~4 yearsAt least as protective as dulaglutide against heart attack, stroke, and CV death12
SUMMIT731 adults with obesity and HFpEF heart failureLower risk of CV death or worsening heart failure vs. placebo16
SYNERGY-NASH190 adults with MASH and liver scarring (phase 2)Liver inflammation resolved in 44–62% vs. 10% on placebo15

What happens if you stop?

Obesity behaves like a chronic condition, and the SURMOUNT-4 trial shows why that matters. Everyone took tirzepatide for 36 weeks and lost an average of 20.9% of their weight. Then half were switched to placebo without knowing it. Over the next year, those who stopped regained an average of 14% of their weight, while those who continued lost another 5.5%.10 A follow-up analysis found that most people who stopped regained more than a quarter of the weight they had lost, and improvements in waist size, cholesterol, and blood sugar reversed along with it.11

What happens when tirzepatide is stopped, SURMOUNT-4 After 36 weeks everyone had lost about 20.9 percent. People who kept taking tirzepatide reached 25.3 percent total loss at week 88; people switched to placebo regained weight and ended at 9.9 percent total loss. Staying on it vs. stoppingSURMOUNT-4: average total weight change from the start of the study0%−10%−20%−30%Everyone on tirzepatideWeek 0Week 36Week 88−20.9%−25.3%kept taking it−9.9%switched toplaceboAverages at the three reported time points; lines connect them. Source: Aronne et al., JAMA 2024.
Weight loss was largely maintained only when treatment continued.10

This doesn't mean you can never stop. It means any plan to stop should be made with your prescriber, with a strategy for nutrition, activity, and follow-up.

Side effects and safety

Common side effects

Most side effects involve the digestive system: nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, and reduced appetite. They are usually mild to moderate and most common when starting or increasing the dose, which is why doses start low (2.5 mg weekly) and rise in 2.5 mg steps no faster than every four weeks, up to a maximum of 15 mg.1 Injection-site reactions, tiredness, and hair thinning have also been reported.

Serious risks to know about

  • Thyroid tumors (boxed warning). Tirzepatide caused thyroid C-cell tumors in rats. Whether this happens in humans is unknown. Do not use it if you or a family member has had medullary thyroid cancer, or if you have MEN 2 syndrome. Report a neck lump, hoarseness, trouble swallowing, or shortness of breath.2
  • Pancreatitis and gallbladder problems. Seek care for severe stomach pain that won't go away, with or without vomiting, or pain in the upper right belly, fever, or yellowing skin.
  • Dehydration and kidney injury from ongoing vomiting or diarrhea.2
  • Low blood sugar when combined with insulin or sulfonylureas.
  • Serious allergic reactions, including swelling of the face or throat.2
  • Pregnancy. It may harm a developing baby. Stop when pregnancy is recognized, and talk with your prescriber if you're planning a pregnancy.2
  • Surgery and anesthesia. Because it slows stomach emptying, tell your surgical team you take it before any procedure that involves sedation.

Brand-name, compounded, and "research" tirzepatide

If you've shopped for tirzepatide, you've likely seen three very different products. The differences matter for your safety.

  • Brand-name (Mounjaro, Zepbound). FDA-approved and made under FDA manufacturing oversight. This is the version tested in every trial cited above.
  • Compounded tirzepatide. Made by pharmacies, and not FDA-approved. Compounding was widely allowed while tirzepatide was in shortage, but the FDA declared the shortage resolved in December 2024.19 In April 2026, the FDA proposed permanently excluding tirzepatide from the list that large outsourcing facilities may compound from.20 Narrow patient-specific compounding by state-licensed pharmacies may still be possible when a prescriber documents a medical need that the approved product can't meet. As of early 2025, the FDA had received more than 320 adverse-event reports tied to compounded tirzepatide, many involving dosing mistakes.21
  • "Research use only" peptides. Sold online as not for human use. They carry no guarantee of identity, purity, sterility, or dose, and have been the focus of FDA warning letters. We don't recommend them.

Key dates

  1. May 2022 · FDA approves Mounjaro for type 2 diabetes
  2. November 2023 · FDA approves Zepbound for chronic weight management
  3. December 2024 · FDA declares the tirzepatide shortage resolved and approves Zepbound for obstructive sleep apnea14,19
  4. April 2026 · FDA proposes ending large-scale compounding of tirzepatide20

Questions to ask your provider

  • Am I a candidate based on my weight, health conditions, and goals?
  • Do I have any personal or family history that rules it out, such as thyroid cancer, MEN 2, or pancreatitis?
  • Which version will I receive, and where is it made?
  • How will we handle side effects and dose increases?
  • How should I adjust protein intake and exercise to protect muscle?
  • What is the long-term plan, including whether and how I would ever stop?

The bottom line

Tirzepatide is one of the most thoroughly studied metabolic medicines available. By copying two gut hormones at once, it reduces appetite, improves blood sugar control, and produces large, well-documented weight loss, with growing evidence for benefits to the heart, kidneys, liver, and sleep. It also has real side effects, works best as a long-term treatment, and is safest in its FDA-approved form under a qualified prescriber's care.

References

  1. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. U.S. FDA; 2026. accessdata.fda.gov
  2. Zepbound prescribing information, patient counseling and warnings. DailyMed, National Library of Medicine. dailymed.nlm.nih.gov
  3. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. insight.jci.org
  4. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology. 2024. frontiersin.org
  5. Thomas MK, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388. academic.oup.com
  6. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. pubmed.ncbi.nlm.nih.gov
  7. Eli Lilly and Company. SURMOUNT-1 results published in NEJM (includes body-composition substudy). 2022. investor.lilly.com
  8. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3-year results). N Engl J Med. nejm.org
  9. Tirzepatide demonstrates superior weight loss to semaglutide in SURMOUNT-5. Applied Clinical Trials. 2026. appliedclinicaltrialsonline.com
  10. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024. pubmed.ncbi.nlm.nih.gov
  11. Horn DB, et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal (SURMOUNT-4 post hoc). JAMA Intern Med. 2026;186(2):157–167. pubmed.ncbi.nlm.nih.gov
  12. SURPASS-CVOT published: large trial confirms CVD efficacy of tirzepatide. TCTMD. December 2025. tctmd.com
  13. SURPASS-CVOT: tirzepatide bests dulaglutide for cardiovascular protection. HCPLive. hcplive.com
  14. Eli Lilly and Company. FDA approves Zepbound as the first prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. December 20, 2024. investor.lilly.com
  15. Loomba R, et al. Tirzepatide for metabolic dysfunction–associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med. 2024;391(4). nejm.org
  16. SUMMIT: tirzepatide improves outcomes and quality of life for patients with HFpEF and obesity. American College of Cardiology. 2024. acc.org
  17. Borlaug BA, et al. Effects of tirzepatide on circulatory overload and end-organ damage in HFpEF and obesity (SUMMIT secondary analysis). Nature Medicine. 2024. nature.com
  18. Unveiling tirzepatide's therapeutic spectrum: a dual GIP/GLP-1 agonist targeting metabolic, neurological, and cardiovascular health. PMC review. pmc.ncbi.nlm.nih.gov
  19. U.S. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. fda.gov
  20. Compounded GLP-1s: why doctors worry and the FDA is cracking down. Stanford Medicine. July 2026. med.stanford.edu
  21. FDA moves to permanently close the door on compounded GLP-1s. Pharmacy Times. September 2026. pharmacytimes.com

This article is for general education and is not medical advice. Tirzepatide is a prescription medicine; talk with a licensed healthcare provider about whether it is right for you. Information is current as of September 2026 and may change as new research and FDA decisions are published. Diagrams are original illustrations by Peptide Advocate.